Table 3.

Multivariate analysis of disease-free and overall survival in young BRCA carriers with pure ductal versus pure lobular breast cancers

	Disease-free survival			Overall survival
	HR	95% CI	P value	HR	95% CI	P value
Histological type			0.536			0.987
Ductal	Ref.	—		Ref.	—
Lobular	1.01	0.74-1.37		0.96	0.62-1.50
Year of diagnosis			0.717			0.047
2000-2004	Ref.	—		Ref.	—
2005-2008	1.07	0.89-1.24		1.33	1.01-1.75
2009-2012	0.97	0.81-1.15		1.32	0.99-1.77
2013-2016	1.03	0.85-1.23		1.61	1.19-2.18
2017-2020	1.10	0.88-1.37		1.63	1.12-2.39
Tumor grade			0.066			0.115
G1	Ref.	—		Ref.	—
G2	1.42	0.85-2.36		1.99	0.73-5.42
G3	1.20	0.71-2.04		1.50	0.54-4.16
Tumor size			<0.001			<0.001
T1	Ref.	—		Ref.	—
T2	1.14	1.01-1.29		1.53	1.24-1.89
T3-T4	1.47	1.23-1.74		2.21	1.70-2.88
Nodal status			<0.001			<0.001
N0	Ref.	—		Ref.	—
N1	1.30	1.14-1.47		1.78	1.44-2.18
N2-N3	1.70	1.44-2.01		2.60	2.02-3.35
Tumor subtype			0.034			0.584
Luminal A	Ref.	—		Ref.	—
Luminal B	1.02	0.80-1.31		1.19	0.81-1.75
TNBC	1.27	0.99-1.63		1.31	0.89-1.93
HER2-positive	1.04	0.79-1.36		1.18	0.76-1.82
Breast surgery			<0.001			0.008
Breast conserving surgery	Ref.	—		Ref.	—
Not done	3.02	1.53-5.95		4.26	1.92-9.46
Mastectomy	0.78	0.70-0.87		1.10	0.92-1.33
Age at diagnosis, years			0.055			0.997
≤35	Ref.	—		Ref.	—
>35	0.91	0.81-1.01		1.01	0.85-1.20
Use of chemotherapy			<0.001			0.025
No	Ref.	—		Ref.	—
Yes	0.60	0.48-0.75		0.57	0.39-0.84
BRCA status			0.827			0.532
BRCA1	Ref.	—		Ref.	—
BRCA2	0.97	0.84-1.12		0.88	0.71-1.10
BRCA1 and BRCA2	0.97	0.53-1.77		1.25	0.51-3.04

CI, confidence interval; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; TNBC, triple-negative breast cancer.